Treatment-naive patients with HCV genotype 1 infection were assigned randomly to 1 of thefollowing groups : PEG-IFN/RBV for 48 weeks ( group A , n = 31 ) , PEG-IFN/RBV for 4 weeks followed by PEG-IFN/RBV for 44 weeks with 6 injections of TG4040 ( group B , n = 63 ) , or TG4040 for 12 weeks ( 7 injections ) followed by PEG-IFN/RBV for 48 weeks with 6 injections of TG4040 ( group C , n = 59 ) .